用于联合或级联抗癌治疗的纳米制剂。
Nanoformulations for combination or cascade anticancer therapy.
作者信息
Miao Lei, Guo Shutao, Lin C Michael, Liu Qi, Huang Leaf
机构信息
Division of Pharmacoengineering and Molecular Pharmaceutics, and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Division of Pharmacoengineering and Molecular Pharmaceutics, and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Key Laboratory of Functional Polymer Materials, Ministry of Education, Institute of Polymer Chemistry, College of Chemistry, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin 300071, China.
出版信息
Adv Drug Deliv Rev. 2017 Jun 1;115:3-22. doi: 10.1016/j.addr.2017.06.003. Epub 2017 Jun 15.
Nanoparticle drug formulations have been extensively investigated, developed, and in some cases, approved by the Food and Drug Administration (FDA). Synergistic combinations of drugs having distinct tumor-inhibiting mechanisms and non-overlapping toxicity can circumvent the issue of treatment resistance and may be essential for effective anti-cancer therapy. At the same time, co-delivery of a combined regimen by a single nanocarrier presents a challenge due to differences in solubility, molecular weight, functional groups and encapsulation conditions between the two drugs. This review discusses cellular and microenvironment mechanisms behind treatment resistance and nanotechnology-based solutions for effective anti-cancer therapy. Co-loading or cascade delivery of multiple drugs using of polymeric nanoparticles, polymer-drug conjugates and lipid nanoparticles will be discussed along with lipid-coated drug nanoparticles developed by our lab and perspectives on combination therapy.
纳米颗粒药物制剂已得到广泛研究、开发，在某些情况下还获得了美国食品药品监督管理局（FDA）的批准。具有不同肿瘤抑制机制且毒性不重叠的药物协同组合可规避治疗耐药性问题，这对于有效的抗癌治疗可能至关重要。与此同时，由于两种药物在溶解度、分子量、官能团和包封条件方面存在差异，通过单一纳米载体共同递送联合方案面临挑战。本综述讨论了治疗耐药背后的细胞和微环境机制以及基于纳米技术的有效抗癌治疗解决方案。将讨论使用聚合物纳米颗粒、聚合物 - 药物偶联物和脂质纳米颗粒进行多种药物的共负载或级联递送，以及我们实验室开发的脂质包被药物纳米颗粒和联合治疗的前景。
Zotero 插件